SCHEMBL7149099

SCHEMBL7149099

COc1ccc(-c2ccc(OC)c3nc(NC(=O)c4ccc(F)cc4)nn23)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.55
MAPT P10636 3/20 0.55
LMNA P02545 3/20 0.50
PDE4D Q08499 5/20 0.49
RECQL P46063 2/20 0.47
OPRK1 P41145 1/20 0.47
CCR6 P51684 1/20 0.47
ADCY1 Q08828 1/20 0.47
JAK1 P23458 3/20 0.47
JAK2 O60674 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
NPC1 O15118 1/20 0.46
HPGD P15428 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
IKBKB O14920 1/20 0.45
RIPK2 O43353 1/20 0.45
LCK P06239 1/20 0.45
TYK2 P29597 1/20 0.45
SYK P43405 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7146843 0.91 LMNA (0.49) KDM4EMAPTLMNAPDE4DADCY1
SCHEMBL7039193 0.91 LMNA (0.61) KDM4EMAPTLMNAPDE4DJAK2
SCHEMBL7140763 0.90 MAPT (0.68) KDM4EMAPTLMNAPDE4DJAK1
SCHEMBL7145623 0.89 LMNA (0.48) KDM4EMAPTLMNAPDE4DJAK2
SCHEMBL7151579 0.85 LMNA (0.46) KDM4EMAPTLMNAPDE4DJAK2
SCHEMBL7145859 0.84 JAK2 (0.54) KDM4EMAPTLMNAPDE4DJAK1
SCHEMBL7143968 0.83 LMNA (0.47) KDM4EMAPTLMNAJAK1JAK2
SCHEMBL6870164 0.83 KDM4E (0.58) KDM4EMAPTLMNAPDE4DJAK2
SCHEMBL6871008 0.82 JAK2 (0.51) KDM4EMAPTLMNAPDE4DJAK2
SCHEMBL7042283 0.80 MAPT (0.56) KDM4EMAPTLMNAPDE4DMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6514989-B1 Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor HOFFMANN-LA ROCHE INC. 2003-02-04 US disclosed
US-6514989-B1 Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor HOFFMANN-LA ROCHE INC. 2003-02-04 US disclosed
US-6514989-B1 Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor HOFFMANN-LA ROCHE INC. 2003-02-04 US disclosed